Efficacy and safety of camrelizumab combined with chemotherapy in the treatment of advanced biliary malignancy and associations between peripheral blood lymphocyte subsets and clinical outcomes

• Jian Zhao ^[1] ; Hongxing Guo ^[1] ; Chenxuan Wu ^[1] ; Hongsheng Guo ^[1]
  1. [1] Tianjin Third Central Hospital

     Tianjin Third Central Hospital

     China

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 27, Nº. 4, 2025, págs. 1658-1667
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background Biliary tract cancer (BTC) is a highly heterogeneous aggressive tumor, and advanced patients have poor prognosis. This work aimed to evaluate the efcacy and safety of camrelizumab combined with chemotherapy in treating advanced BTC, and to explore predictive biomarkers for distinguishing efective population.

    Methods 183 advanced BTC patients admitted from September 2018 to September 2021 were retrospectively selected. 93 patients were treated with camrelizumab combined with chemotherapy (C+C group) and 90 patients were treated with chemotherapy alone (C group). Objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), and median overall survival (mOS) were analyzed between two groups. Peripheral blood lymphocyte subsets were assessed by fow cytometry pre- and post-treatment.

    Results The mPFS (6.9 months) and mOS (12.1 months) in the C+C group were signifcantly longer than those in the C group, which were 5.2 months and 9.8 months respectively (HR 0.46, 95% CI 0.38–0.54, p=0.017; HR 0.39, 95% CI 0.32–0.47, p=0.033). The percentage of Total T, CD4+T, natural killer (NK) cells, lymphocyte, and CD4+/CD8+ cell ratios were signifcantly increased in efective patients after C+C treatment, but didn’t increase in progressive disease (PD) patients. Higher percentage of Total T, CD4+T, and higher CD4+/CD8+ cell ratios post-treatment were associated with longer OS.

    Conclusions Camrelizumab combining chemotherapy signifcantly prolonged the mPFS and mOS of advanced BTC patients. Immunotherapy may improve the immune status of advanced patients, and immunotherapy efcacy might be predicted based on the peripheral blood lymphocyte subsets.